Samsung applies for approval of Humira biosimilar

Published: 2016-09-28 16:06:51

Updated: 2016-09-28 16:06:51

Samsung is about to secure a pipeline with biosimilars of the top 3 ‘TNF-alpha inhibitors.’

After a ‘Enbrel(etanercept)’ similar, ‘Lenflexis,’ and a ‘Remicade(infliximab)’ similar, ‘Brenzys,’ the company filed for approval of the top product ‘Humira(adalimumab)’ similar, ‘SB5.’

Samsung Bioepis is also working on getting approval of SB5 in Europe. Moreover, Lenflexis is in the progress of acq...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.